Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glypican 5 antisense RNA 1 (non-protein coding) (GPC5-AS1)
- Target
- GPC5-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Non-coding RNA, Epigenetic/transcriptional regulator (functional classification)
01
Overview
Glypican 5 antisense RNA 1 (GPC5-AS1) is a long non-coding RNA transcribed from the antisense strand relative to the GPC5 gene on chromosome 13q31.3. GPC5-AS1 functions as an endogenous molecular sponge for microRNAs miR-93 and miR-106a, protecting GPC5 mRNA from degradation and thereby enhancing the expression of this putative tumor suppressor. In gastric cancer, GPC5-AS1 is frequently downregulated, contributing to increased cell proliferation, impaired apoptosis, and accelerated tumor progression. Overexpression of GPC5-AS1 can suppress gastric cancer cell growth, induce apoptosis, and retard tumorigenesis in vitro and in vivo. Epigenetically, the promoter activity of GPC5-AS1 is regulated by methyl-CpG-binding protein 2 (MeCP2), affecting its expression in cancer cells. Studies suggest GPC5-AS1 may serve as both a diagnostic biomarker and a promising therapeutic target for gastric cancer. Its roles in other cancer types are under bioinformatic investigation, though experimental evidence is limited beyond gastric cancer[1][2][3][4].
- Other names
- GPC5 antisense RNA 1 (non-protein coding)GPC5-AS1ENSG00000235984NCBI Gene: 100873969HGNC: 39886GC00U933069GC13M093354
02
Biological functions
Regulation of gene expression (stabilizes GPC5 mRNA by acting as a molecular sponge for microRNAs miR-93 and miR-106a)Suppression of cell proliferationInduction of apoptosisModulation of cell cycle transitionPotential involvement in epigenetic regulation through interaction with methyl-CpG-binding protein 2 (MeCP2)Competing endogenous RNA (ceRNA) activity
03
Disease associations
Gastric cancer (tumor suppressor role)Potentially implicated in metastatic melanoma, renal cell cancer, astrocytoma, and meningioma (based on bioinformatic analyses; experimental evidence is strongest for gastric cancer)
04
Safety considerations
Delivery challenges for lncRNA-based therapiesPotential off-target effects of lncRNA-based therapies
05
Biomarkers
Expression level of GPC5-AS1 in tumor tissue (potential diagnostic biomarker for gastric cancer)Expression status of GPC5 (host gene)Levels of miR-93 and miR-106a (inverse correlation with GPC5-AS1, mechanistic relevance)
Beyond the preview
Go deeper on Glypican 5 antisense RNA 1 (non-protein coding) (GPC5-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Glypican 5 antisense RNA 1 (non-protein coding) (GPC5-AS1).